Records 1-20 (of 20 Records) |
Query Trace: Genomic medicine[original query] |
---|
The landscape of mRNA nanomedicine X Huang et al, Nature Medicine, November 10, 2022
Messenger RNA (mRNA) is an emerging class of therapeutic agent for the prevention and treatment of a wide range of diseases. The recent success of the two highly efficacious mRNA vaccines to protect against COVID-19 highlights the huge potential of mRNA technology for revolutionizing life science and medical research. Challenges related to mRNA stability and immunogenicity, as well as in vivo delivery and the ability to cross multiple biological barriers, have been largely addressed. In this Review, we present the latest advances and innovations in the growing field of mRNA nanomedicine, in the context of ongoing clinical translation and future directions to improve clinical efficacy.
|
Association of ACE1 I/D rs1799752 and ACE2 rs2285666 polymorphisms with the infection and severity of COVID-19: A meta-analysis. Aziz Md Abdul, et al. Molecular genetics & genomic medicine 2022 0 0. e2063 |
A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility. Voloudakis Georgios, et al. NPJ genomic medicine 2022 0 0. (1) 52 |
A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility G Voloudakis et al, NPJ Genomic Medicine, September 5, 2022
Using a translational genomics approach that integrates COVID-19 genetic susceptibility variants, multi-tissue genetically regulated gene expression (GReX), and perturbagen signatures, we identified IL10RB as the top candidate gene target for COVID-19 host susceptibility. In a series of validation steps, we show that predicted GReX upregulation of IL10RB and higher IL10RB expression in COVID-19 patient blood is associated with worse COVID-19 outcomes and that in vitro IL10RB overexpression is associated with increased viral load and activation of disease-relevant molecular pathways.
|
New Insights on Circular RNAs and Their Potential Applications as Biomarkers, Therapeutic Agents, and Preventive Vaccines in Viral Infections: with a glance at SARS-CoV-2. Rahmani-Kukia Nasim, et al. Molecular therapy. Nucleic acids 2022 0 0. |
B cell-derived cfDNA after primary BNT162b2 mRNA vaccination anticipates memory B cells and SARS-CoV-2 neutralizing antibodies. Fox-Fisher Ilana, et al. Med (New York, N.Y.) 2022 0 0. |
The use of telemedicine in cardiogenetics clinical practice during the COVID-19 pandemic. Liang Lusha W, et al. Molecular genetics & genomic medicine 2022 0 0. e1946 |
Integrative transcriptomic, evolutionary, and causal inference framework for region-level analysis: Application to COVID-19. Zhou Dan, et al. NPJ genomic medicine 2022 0 0. (1) 24 |
Integrative transcriptomic, evolutionary, and causal inference framework for region-level analysis: Application to COVID-19 D Zhou et al, NPJ Genomic Medicine, March 22, 2022
We developed an integrative transcriptomic, evolutionary, and causal inference framework for a deep region-level analysis, which integrates several published approaches and a new summary-statistics-based methodology. To illustrate the framework, we applied it to understanding the host genetics of COVID-19 severity. We identified putative causal genes, including SLC6A20, CXCR6, CCR9, and CCR5 in the locus on 3p21.31, quantifying their effect on mediating expression and on severe COVID-19. We confirmed that individuals who carry the introgressed archaic segment in the locus have a substantially higher risk of developing the severe disease phenotype.
|
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data J Lanillos et al, NPJ Genomic Medicine, February 18, 2022
we carried out a systematic analysis based on 5001 Spanish or Latin American individuals with diagnostic exome data, either Whole Exome Sequencing (80%), or the so-called Clinical Exome Sequencing (20%) (60?Mb and 17?Mb, respectively), to provide with global and gene-specific clinical pharmacogenetic utility data. 788 pharmacogenetic alleles, distributed through 19 genes included in Clinical Pharmacogenetics Implementation Consortium guidelines were analyzed. Each individual carried in average 2.2 alleles and overall 95% (n?=?4646) of the cohort could be informed of at least one actionable pharmacogenetic phenotype. Differences in variant allele frequency were observed among the populations studied and the corresponding gnomAD population for 7.9% of the variants.
|
AI for COVID-19: Battling the pandemic with computational intelligence. Xu Zhenxing, et al. Intelligent medicine 2021 0 0. |
TBK1 and TNFRSF13B mutations and an autoinflammatory disease in a child with lethal COVID-19. Schmidt Axel, et al. NPJ genomic medicine 2021 0 0. (1) 55 |
Ethically utilising COVID-19 host-genomic data. Gyngell Christopher et al. NPJ genomic medicine 2021 5 (1) 31
Genetic variants that influence susceptibility to COVID-19 have recently been identified. In this manuscript, we identify and discuss some of the ethical and practical issues raised by these studies. We first outline the ethical case for providing COVID-19 susceptibility testing to healthcare workers, as well as highlighting risks associated with privacy and discrimination. We then argue that the existence of genetically susceptible individuals has implications for the ethical conduct of COVID-19 human challenge trials.
|
Investigating the ACE2 polymorphisms in COVID-19 susceptibility: An in silico analysis. Pouladi Nasser, et al. Molecular genetics & genomic medicine 2021 4 0. e1672 |
Pathology Trainee Redeployment and Education During the COVID-19 Pandemic: An Institutional Experience. Monroig-Bosque Paloma Del C, et al. Academic pathology 0 0 0. 2374289520953548 |
How digital tools can advance quality and equity in genomic medicine. Bombard Yvonne, et al. Nature reviews. Genetics 2020 0 0. (9) 505-506 |
Pharmacogenomics of COVID-19 therapies. Takahashi Takuto et al. NPJ genomic medicine 2020 8 35
We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). We also identified other variants, that are associated with adverse effects.
|
Single-cell RNA sequencing analysis of human kidney reveals the presence of ACE2 receptor: A potential pathway of COVID-19 infection. He Qiyu, et al. Molecular genetics & genomic medicine 2020 8 0. e1442 |
Genetic counseling during COVID-19 pandemic: Tuscany experience. Pagliazzi Angelica, et al. Molecular genetics & genomic medicine 2020 8 0. e1433 |
Genetic variability of human angiotensin-converting enzyme 2 (hACE2) among various ethnic populations. Li Quan, et al. Molecular genetics & genomic medicine 2020 6 0. e1344 |
Disclaimer: Articles listed in the Public Health
Knowledge Base are selected by the CDC Office of Public Health
Genomics to provide current awareness of the literature and news.
Inclusion in the update does not necessarily represent the views of
the Centers for Disease Control and Prevention nor does it imply
endorsement of the article's methods or findings. CDC and DHHS assume
no responsibility for the factual accuracy of the items presented. The
selection, omission, or content of items does not imply any
endorsement or other position taken by CDC or DHHS. Opinion, findings
and conclusions expressed by the original authors of items included in
the update, or persons quoted therein, are strictly their own and are
in no way meant to represent the opinion or views of CDC or DHHS.
References to publications, news sources, and non-CDC Websites are
provided solely for informational purposes and do not imply
endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:May 01, 2024
- Content source: